Forms

*These are examples of possible forms to use from Idaho and other states.

CONTENTS

Introduction 17.2

Diagnosis/Assessment Forms

Confirmed/Suspected Report of Tuberculosis Disease (MT)

TB Diagnostic Referral Form (MT)

Bacteriology Data Sheet (MT)

Biochemistry Data (MT)

TB Home Evaluation (MT)

Address Information Request (OR)

TB Medication and Side Effect Surveillance Forms

See also the Bacteriology Data Sheet and Biochemistry Data Forms listed above.

Idaho Tuberculosis Drug

Assistance Program Order Form (ID)

Panhandle Health District's

TB Drug Interview Sheet (ID)

Adverse Reactions & Side Effects

to TB Medications (MT)

Visual Acuity and Ishihara's Tests for Color

Blindness - Test Results (OR)

Treatment of Active

Tuberculosis (TB) Education Form (MT)

Treatment of LTBI

(Latent TB Infection) Education Form (MT)

Usual Length of TB Treatment

Plan (visually depicted) (OR)

Tuberculosis Treatment Agreement (English) (WA)

Tuberculosis Treatment Agreement (Spanish) (WA)

Case Management/DOT Forms

Case Management Treatment Planfor Active TB Disease

TB Disease Monthly Patient Assessment (MT)

Monthly Tuberculosis Case Report (MT)

LTBI Monthly Patient Assessment (MT)

TB Case Management Monitoring Record (OR)

Critical Pathway (WA)

(Case Management/DOT Forms-continued)

Tuberculosis Treatment Record Directly Observed

Therapy - DOT (MT)

Tuberculosis (TB) Directly Observed Therapy

Agreement (MT)

Directly Observed Therapy Record (ID)

Contact Investigation Forms

Idaho TB Contact Tracing Form (ID)

TB Contact Investigation report (MT)

Tuberculosis Contact Investigation Form (WA)

TB Contact Investigation Summary (MT)

Isolation Forms

Home Isolation Agreement (MT)

Home Isolation Agreement (OR)

Instructions for Patient with Infectious Tuberculosis (TB)

and Home Isolation Agreement (ID)

Isolation Instructions (English) (WA)

Isolation Instructions (Spanish) (WA)

Voluntary Isolation/Quarantine Agreement

(English) (WA)

Voluntary Isolation/Quarantine Agreement

(Spanish) (WA)

Orders to Voluntarily Comply with Tuberculosis

Control Measures (OR)

Transfer Notification Forms

Interjurisdictional Tuberculosis

Notification (MT)

Interjurisdictional Follow-up Form (MT)

ID = Idaho

MT = Montana

OR = Oregon

WA = Washington

Introduction

The forms on the following pages are a collection of examples of various case management and data collection forms from TB programs in Idaho, Montana, Oregon and Washington State. Most of the forms are available electronically as MS Word documents. The MS Word files can be requested from the Idaho TB program at 208-334-5939.

While the all forms included in this section are meant to be resources, the following reports are required by the contract with the Idaho State TB Program:

Report Title	When Due
RVCT form*	When information is available
RVCT follow-up 1 form*	When sensitivities are available, or, if culture negative, once the laboratory declares the specimens to be culture negative.
RVCT follow-up 2 form*	At the end of regimen
Directly Observed Therapy Record	At the end of regimen
Contact Tracing Form	Return with RVCT Follow-up 2 form or when contacts complete evaluation or treatment
TB Control Activities Quarterly Report [†]	Quarterly

^{*}The RVCT forms are not available in electronic format.

[†]The Quarterly Report is not included in this manual, but can be requested at from the Idaho TB program.

CONFIRMED/SUSPECTED REPORT OF TUBERCULOSIS DISEASE

Montana Department of Public Health & Human Services Today's Date: _____ TB Program, Cogswell Building, Room C-216 Submitted By: 1400 Broadway, Helena, MT, 59620 Phone: 406-444-0275; Fax: 406-444-0272 Phone: Patient Name: _____ Age: ___ DOB: _____ City: _____ State: ___ Zip Code: _____ Country of Origin: _____ If not USA, month & year of Immigration: _____ Race: () White Ethnic Origin: () Native American () Other, specify: Gender: () Female Ethnic Origin: () Hispanic () Non-Hispanic () Male Re-disease after 12+ months of inactivity: () Yes () No List year of previous diagnosis: _____ Diagnosis reported at time of death: () Yes Date expired: () No Contact of known TB case: Name of case: () Yes () No 1. Tuberculin Skin Test Results: Date: _____ mm of Induration: ____ Date: ____ Results: 2. X-Ray Results: Attach X-ray results Date: _____ Results:____ 3. HIV Results: 4. Bacteriological Results: If state lab is not used, attach lab results. If state lab is used, results are on file at the TB program. Initial Medication Regime: () INH () Rifampin () Pyrazinamide () Ethambutol () Other _____ Date Therapy Started: DOT Plan: (dose, freq, location) Brief Clinical History: Resident of Correctional Facility: () Yes () No Resident of Long-term Care Facility: () Yes () No Homeless within the last year: () Yes () No Occupation: Check all that apply within the past 24 months Facility Name: Facility Name: Shelter Name: () Health Care Worker () Migratory Agricultural Worker () Unknown () Correctional Worker () Not employed past 24 months () Other specify: ______ Injecting Drug use within Past Year: () Yes () No () Unknown Non-injecting Drug use within Past Year: () Yes () No () Unknown Excess Alcohol Use within Past Year: () Yes () No () Unknown Organ Transplant: () Yes () No () Unknown Transplant Date: _____ Type: _____

Attending Physician: _____ Phone:____

Public Health Case Manager: _____ Phone:___

TB DIAGNOSTIC REFERRAL FORM: Active TB Disease or Latent TB Infection (LTBI) ONLY

	loday's Date
Agency	Contact
Address	
Phone/Fax	
Patient Name	
	City
	Sex Race
	Phone
	Phone
T de lie Treatur Mariager	
This person is bein	g referred because he/she had a Positive Tuberculin/TST Result:
Date	Induration in mm
December TCT/Marshay	() Combact of language TD coop
Reason for TST/Mantou	
	() Foreign born; Country of origin
	() Occupational
	() Other
	IC TESTS REQUIRED: (Core Curriculum; 4 th Edition, 2000)
A complete medical evalu	nation for TB includes: 1. Tuberculin/TST skin test; 2. Chest X-ray;
3. Medical history; 4. Pl	nysical examination; and 5.Bacteriological or histologic exam if needed
based on symptoms and	chest X-ray
Chest X-ray	Date
	Results
	Previous X-ray dates & results
Symptoms	() Productive, prolonged cough () Chest pain () Hemoptysis
J	() Weight loss () Appetite loss () Tires easily () Night sweats
	() Fever () Chills
	() Tever () Clinis
Physical Exam	
i ilysicai Exam	
D' 1 E (
Risk Factors	<u>Liver Disease</u> ()Yes ()No () Hepatitis A, B or C Type
For Treatment	<u>Diabetes</u> ()Yes () No ()Type I ()Type II
	Organ Transplant ()Yes ()No Date Type
	<u>Injecting Drug Use</u> within the past year ()Yes ()No
	Non-Injecting Drug Use within past year ()Yes ()No
	Excess Alcohol Use within past year ()Yes ()No
	Other Comments:

Diagnosis	() Presumptive/Active TB - notify your local health department ASAP () Latent TB Infection (LTBI), Active TB Disease ruled out.
*Treatment I	.TBI
* Until Active	TB disease is completely ruled out, <u>DO NOT</u> start patient on medications for treatment for
Latent TB Infec	tion (LTBI).

Treatment recommendations for Latent TB Infection: <u>1.</u> A 9-month regimen of INH is considered optimal for both HIV-positive and HIV-negative adults; <u>2.</u> A 6-month regimen may also provide sufficient protection. <u>3.</u> Pyridoxine (Vit B6) is often given to reduce the incidence of INH induced peripheral neuropathy when INH doses exceed 5mg/kg or the patient has HIV, diabetes, alcoholism, malnutrition, pregnant, seizures. Core Curriculum on TB, 4th Edition, 2000. http://www.cdc.gov/nchstp/tb/pubs;slidesets/core/html/trans6-slides.htm

Monitoring Protocol

- 1. Baseline liver panel for patients with HIV, alcoholism, history of liver disorder, risk for liver disorder, pregnant and immediate postpartum
- 2. Monthly follow-up to evaluate adherence and signs & symptoms of active disease
- 3. Weekly to monthly (depending on meds) follow-up to evaluate for signs & symptoms of hepatitis

Physician	Phone

Your Local Health Department offers the following services for patients with Active TB Disease and Latent TB Infection (LTBI):*

- 1. Help obtaining anti TB medications
- 2. Regular monitoring of patient adherence
- 3. Regular monitoring of patient's for changing signs and symptoms of TB
- 4. Regular monitoring of adverse reactions to anti TB medications
- 5. Regular communication with prescribing physician

*If you are referring this patient to the health department for treatment monitoring
please send the original Rx for INH and Pyridoxine (if prescribed) to your local
health department or with the patient.

Please return this form to the	
	(Local health department name & contact person)

Bacteriology Data Sheet

Patient Name		

Lab Number	Submitted By	Date Collected	Date Received	AFB Smear Results	Date Reported	Culture Results	Date Reported	NAA Results	Date Reported

Susceptibility Results:

Date	INH	S/R
Date	RIF	S/R
Date	EMB	S/R
Date	PZA	S/R
Date	STREP	S/R
Date		S/R

	BIOCHEMISTRY DATA							
Patient name	e:						 	
DATE								
WBC								
RBC								
HGB								
PLT								
AST								
ALT								
TBIL								
DBIL								
ALKPHOS								
ALBUM								
Serum Drug Levels								
INH								
RIF								
EMB								
PZA								
DATE								
WBC								
RBC								
HGB								
PLT								
AST								
ALT								
TBIL								
DBIL								
ALKPHOS								
ALBUM								
Serum Drug Levels								
INH							 	
RIF								

EMB PZA

TB HOME EVALUATION

Home Environment
Client has own room: ☐ Yes ☐ No # bedrooms/comments:
in dwelling: Adults Children Among them, Immunosupressed: \(\subseteq \text{Yes} \subseteq \text{No} \) Who
Home safety/ adaptive equipment: ☐ Yes ☐No Specify Pets ☐ Yes ☐No
Understanding of Disease Education: □ < High School □High School □College □College + Drug/Alcohol Risk Factors: □ Yes □No □ N/A, if yes, willing to seek TX □ Yes □No Adequate knowledge of tuberculosis transmission: □ Yes □No Medications: Adequate understanding of medication side effects: □ Yes □No Adequate understanding of medication schedule: □ Yes □No Possible drug interaction: Treatment Plan: Understands need to keep doctor/clinic appointments: □ Yes □No Understands need to comply with requests for CXR/Lab/ DOT: □ Yes □No Assessment/Comments: Social Interaction Adequate culturally appropriate social support system: □ Yes □No If Yes, Whom: Lifestyle consistent with treatment adherence: □ Yes □No Language limitations: □ Yes □No Assessment/Comments:
Transportation Client has a car: □ Yes □No Relative/Friend will transport? □ Yes □No Client needs transportation: □ Yes □No Client has access to bus service: □ Yes □No Knowledge of transportation assistance: □ Yes □No Client will need bus incentive: □ Yes □No Assessment/Comments:
Financial Source of income: Other sources: □Food Bank □Medicare □Food Stamps □WIC □ SSI □Other (Specify):
Date: Signature:

MT DPHHS 2/2007

Copy on your letterhead

Date	:	
То:	Postmaster, Oregon	
indiv indiv	se furnish this agency with the new according to the second of the secon	ormation Request Idress, if available, for the following Iress given below is one at which mail for this the following address is a post office box, Ided on the boxholder's application form.
Nam	e:	
Last	known address:	
	tity that the address information for the is agency's official duties. Name	Title
	FOR POST O	FFICE USE ONLY
() N () N () N	Mail is delivered to address given Not known at address given Moved, left no forwarding address No such address Other (specify):	New Address Boxholder's Street Address:
_	ncy's Return Address: er letterhead	
	Pos	stmark/Date Stamp

Idaho Tuberculosis Drug Assistance Program Order Form

Physician Ship to:	Patient:
	Date of Birth:
	Order Date:
	Telephone:

^{**}Only order three (3) months supply at one time. You will need to re-order as needed.**

Product No.	Amt.	Product	Price
3753-1		package(s) of Pyridoxine, 25 mg, (Vitamin B6), 100 tablets per package	0.00
2509-3		bottle(s) of Isoniazid, 300 mg, (INH), 30 tablets per bottle	0.00
2900-0		bottle(s) of Isoniazid syrup (INH), 1 pint bottle	0.00
2942-0		bottle(s) of Isoniazid, 100 mg, (INH), 100 tablets per bottle	0.00
3070-0		bottle(s) of Ethambutol, 400 mg, (EMB), 60 tablets per bottle	0.00
3950-0		bottle(s) of Pyrazinamide, 500 mg, (PZA), 100 tablets per bottle	0.00
8621-0		bottle(s) of Rifampin, 300 mg, (RIF), 60 capsules per bottle	0.00
		TOTAL COST:	\$ 0.00

Direct questions to: Sybrina Bobo **Phone:** (208) 334-5939 **Fax:** (208) 332-7307

Office of Epidemiology and Food Protection Idaho Department of Health and Welfare 450 West State Street, 4th Floor PO Box 83720 Boise, ID 83720-0036

FOR OFFICE US	SE ONLY
Account No:	6738

Confirmation No:

Invoice Amount: _____

6/22/07

PANHANDLE HEALTH DISTRICT TB DRUG INTERVIEW SHEET

Client Name:

	<u>Date</u>								
N									
Nurse's Initials:									
HEPATOTOXICITY(ALL)									
Icterus (Jaundice)	ΥN								
Nausea	ΥN								
Vomiting	ΥN								
Abd Pain (RUQ)	ΥN								
Fever x 3 days or more	ΥN								
Light Stools	ΥN								
Dark urine	ΥN								
HYPERSENSITIVITY(ALL)									
Rash	ΥN								
Arthralgia (Joint Pains)	ΥN								
NON-SPECIFIC (ALL)									
Headache	ΥN								
Malaise	ΥN								
Fatigue	ΥN								
Anorexia (Loss of Appetite)	ΥN								
NEUROTOXICITY(INH,EMB)									
Paresthesia (Numbness,	ΥN								
Tingling)	ΥN								
Hearing-decrease	ΥN								
Balance-decrease	ΥN								
Dizziness	ΥN								
Visual-decrease/change	ΥN								
Acuity	ΥN								
• Color	ΥN								
HEME (RIF)									
Bruising-increase	ΥN								
Bleeding gums	ΥN								
Hematuria (Blood in urine)	ΥN								
Hematochezia (Blood in	ΥN								
stool)									

CIRCLE "Y" FOR YES AND DESCRIBE IN PATIENT PROGRESS NOTES CIRCLE "N" FOR NO

Adverse Reactions & Side Effects to TB Medications

(Use with DOT Treatment Record Form)

Patient	's N	lame:
---------	------	-------

				Comments
Date				
PHN Initials				
Hepatotoxicity INH,RIF,EMB,PZA				
Jaundice				
Nausea				
Vomiting				
Abd Pain				
Fever > 3 days				
Light stools				
Dark urine				
Hypersensitivity INH,RIF,EMB,PZA				
Rash				
Joint Pains				
Non-specific INH,RIF,EMB,PZA				
Headache				
Malaise				
Fatigue				
Loss of Appetite				
Neurotoxicity INH, EMB				
Numbness/tingling				
Hearing decrease				
Balance decrease				
Dizziness				
Vision changes				
Color				
Hemolytic RIF				
Bruising – increase				
Bleeding gums				
Blood in urine				
Blood in stool				

If any of these are present, describe in Monthly TB Patient Assessment and call treating MD ASAP.

MT DPHHS 2/2007

VISUAL ACUITY AND ISHIHARA'S TESTS FOR COLOR BLINDNESS - Test Results Page _____ Client Name ______ D.O.B _____/____ MR #:_______

	Lastiname	i list Name										
Legend from Isl	nihara's Tests for Co	olour Deficiency	BASE	LINE		(Client's Visu	ual Acuity a	nd Ishihara [°]	Test Results	3	
Of Unlettered Persons			Date	Tool*	Date	Tool*	Date	Tool*	Tool*	Tool*	Date	Tool*
	Person		Od(right eye)		od		od		od		od	
Number	with	Person with	OS(left eye)		os		os		os		os	
of	Normal	Red-Green	Ou (both eyes)		ou		ou		ou		ou	
Plate	Color	Deficiencies	glasses	Yes/No	glasses	Yes/No	glasses	Yes/No	glasses	Yes/No	glasses	Yes/No
	Vision								and show the	patient what	forms they	will be
1	0	0	asking the patient to identify and to verify patient's understanding. 2. For Plates 3,4,5,6,7, and 8: check (4) the appropriate column: "Norm" if patient result indicates normal; "Def" if the patient result indicates a deficiency. Mark (X) in the "Def" box if the patient can not read the plate.						ef" if the			
2			Norm	Def	Norm	Def	Norm	Def	Norm	Def	Norm	Def
3	0											
4		0										
5	>	ζ										
6	Red curve	Blue curve										
7	Upper Green curve	Lower Red curve										
8	X to X & back up to the starting X via the other line	Unable to trace, or Only traces one line X to X										
		Nurse's Signature										
Ishihara should be u on EMB, including p		**Interpretation /										
age or persons who		Comments (Action)										
**Interpretation of Acuity & Ishihara results				*Tool	A = 10 foot	acuity chart-	Brand: Snel	len. Sloan.	other			

- 1. Stable for the patient: if no change from baseline
- 2. Abnormal:
 - Visual acuity changes more than one line from baseline.
 - Ishihara: can't recognize any curve in Plate #8.
 - : Questionable- if misjudges more than 3 plates among # 3,4,6,and 7.
 - : **Re-test-** if misjudges on 1 or 2 plates among # 3,4,6, and 7.

*Tool	A = 10 foot acuity chart- Brand:	Snellen,	Sloan,	other
	B = 20 foot acuity chart- Brand:	Snellen,	Sloan,	other_
	C = other:			

Action: Follow-up recommendations for changes from baseline-

Baseline Test: no follow-up needed if Ishihara deficiency noted before EMB was started.

Susequent Test: - No change from baseline, or only 1 line change: No follow-up needed.

- Change from baseline: **Stop EMB if** decrease of acuity by 2 or more lines or any change is noted on Ishihara *from baseline* and refer to PMD for further evaluation.

^{**}follow instructions provided by the tool's manufacturer

12/12/02

- 1. Fill in the patient's name, DOB, medical record #.
- 2. Fill in page number (eg/ for patients on EMB for extended periods of time).
- 3. For both the Visual Acuity and Ishihara tests, follow the manufacturer's instructions for administering the test.
- 4. Circle the type of visual acuity tool used or enter the name of the tool used, if it's not listed. The same tool should be used from test to test.
- 5. Visual Acuity Section:
 - fill in the date of the test, and the tool used (per code at bottom of the page)
 - enter the visual acuity score for the right eye, left eye, both eyes, and indicate if corrective lenses were used by circling "glasses" Yes or No.
- 6. Ishihara Section:
 - a. Demonstrate what you are looking for, O or □, in plates 1 and 2. Have patient do a return demonstration to assure they understand the instructions.
 - b. For plates 3-8, check (4) the column which indicates the color detection ability of the patient: check (4) the "Norm" column if they scored normal, check (4) the "Def" column if the patient result indicates a deficiency in color vision. Mark (X) if the patient does not recognize any design in the plate. (For each plate, there is a column in the legend that reminds you what a normal and what a deficient person sees)
- 7. Compare the baseline to the current test result.
 - a. On baseline test (done before the patient starts EMB)
 - 1) If visual acuity is abnormal, refer to MD for further evaluation and corrective lens as indicated.
 - If patient obtains corrective lenses (contacts or glasses), repeat the test to establish a new baseline with corrective lenses.
 - 2) If red-green deficiencies identified, no follow-up is indicated. If unable to recognize any of the shapes, refer to PMD for follow-up.
 - b. On subsequent tests:
 - 1) No follow-up is needed if there is no change in visual acuity /Ishihara; or, only 1 line change in visual acuity.
 - 2) **Stop EMB** *if* there is a decrease of acuity by <u>2 or more</u> lines, or <u>any</u> change is noted on Ishihara. Refer to PMD for further evaluation and recommendation regarding continued use of EMB.
- 8. Sign in the Nurse's signature box.
- 9. Indicate "interpretation" by using the "Interpretation of Acuity & Ishihara results legend in the lower left corner of the form.
 - -Note, if patient misjudges 1 or 2 plates (among plates 3,4,6,&7), and that is different from the baseline, repeat the test. If it is still a change from baseline, stop the EMB and call the PMD to report the findings and refer patient for further evaluation.
 - a. If there is no change in visual acuity /Ishihara; or, only 1 line change in visual acuity, write in "stable".
 - b. If there is a decrease of acuity by <u>2 or more</u> lines, or <u>any</u> change is noted on Ishihara, write in "abnormal" and where to look for notes explaining your intervention.

Treatment of Active Tuberculosis (TB) Education Form

Public Health N	urse:	_			
Agency:		_			
Phone:		_			
Dear Client:					
This is to inform	you about the treatment, side effect	ts and risks of taking medication for active tuberculosis disease.			
	tive TB with prescribed drugs will in according to your physician's prescribed	n most cases cure TB. The medication needs to be taken from 6 cription and instructions.			
Medication	Side Effects	Comments			
Isoniazid (INH)	Dark Urine, Light-colored Stools, Fatigue, Loss of Appetite, Nausea, Vomiting, Abdominal Pair Yellow Eyes or Skin, Rash, Tingling or Muscle Twitching in hands or feet	Do not take Tylenol (acetaminophen) or any medication with			
Rifampin (RIF)	Orange colored body fluids, Flu-like Symptoms, Nausea, Vomiting, Abdominal Pair Bleeding Problems, Fever, Light-colored Stools, Rash, Yellow Eyes or Skin, Fatigue, Blood in Urine, Bruise Easily	Do not use alcohol because of risk of liver damage. Significant interactions with methadone, birth control meds, digitalis, coumarin derivatives, anticonvulsants, PIs, NNRTIs, and many other drugs. Colors body fluids orange (i.e. sweat, urine, tears). May permanently discolor soft contact lenses. Tell your doctor or public health nurse if you become pregnant while on INH.			
Pyrazinamide (PZA)	Dark Urine, Light-colored Stools, Yellow Eyes or Skin, Joint Aches, Upset Stomach, Nausea, Vomiting Fatigue, Rash, Photosensitivity, Go	Do not use alcohol because of risk of liver damage. Drink plenty of fluids (water, juices, milk). May cause elevated uric			
Ethambutol (EMB)	Any Changes in Vision, (Ability to see or discriminate color Skin Rash	Do not use alcohol because of risk of liver damage. Not recommended for children who are too young to be monitored for vision changes.			
CALL: If yo	u have any of the side effects lis	sted above or			
	u have any questions:				
		atment of active TB disease. I have had an opportunity to ask I believe I understand the benefits and risks of taking these			
Client name, ple	ease print Dav	te of Birth Today's Date			
Client or author	zed person signature Pub	olic Health Nurse Signature			
List educationa	l material given to client:				
Gave client a co	opy of form:(Pl	HN Initials) MT DPHHS 2/2007			

Treatment of LTBI (Latent Tuberculosis Infection) Education Form

blic Health Nurse	:					
gency:		Phone:				
eatment of latent 7	ΓB infection, as prescribed, will μ	and risks of taking medication for latent TB infection. revent active TB disease from developing in most individuaccording to your physician's prescription and instructions INH.				
Medication	Side Effects	Comments				
Isoniazid (INH)	Dark Urine, Light-colored S Fatigue, Loss of Appetit Nausea, Vomiting, Abdomina Yellow Eyes or Skin, Ras Tingling or Muscle Twitch in hands or feet	Do not take Tylenol (acetaminophen) or any medication with Tylenol while on INH. You can take Ibuprofen, Aleve or Advil. Avoid entering (Mooley, Tymes, Mylente), within 2				
Rifampin (RIF)	Orange colored body fluid Flu-like Symptoms, Nausea, Vomiting, Abdominal Bleeding Problems, Fever Light-colored Stools, Rasl Yellow Eyes or Skin, Fatig Blood in Urine, Bruise Eas	control meds, digitalis, coumarin derivatives, anticonvulsants, PIs, NNRTIs, and many other drugs Colors body fluids orange (i.e. sweat, urine, tears). May permanently discolor soft contact lenses. e, Tell your doctor or public health nurse if you				
If you have read the stater	ave any of the side effects listed ave any questions: ments on this form about the treat					
	print Date	of Birth Today's Date				
ent name, please						

MT DPHHS 2/2007

Gave client a copy of form: _____ (PHN Initials)

Usual Length of TB Treatment Plan

(teaching tool for TB nurses to explain to patients why they need to take medicine for so long)

When Diagnosed	1 st Month	2 nd Month	3 rd Month	4 th Month	5 th Month	6 th Month	or longer
Sick	Better	Better	Feel well	(i)	<u></u>	<u></u>	IONGU
		$\stackrel{\boldsymbol{\omega}}{=}$			0		Q
Lab Tests	+++	+	(-)	(-)	(-)		Sometimes
Smear	(or -) ++ (or -)	(or -) + (or -)	(-) (or +)	(-)	(-)		people need to take medicine longer: * Cavitary TB *Culture + after 2months meds
TB Medicine							

Developed by Evelyn Lancaster, RN, PHN - TB Controller Oregon: revised 5/03, 1/04



tpchd.org

3629 S. D Street MS 421 Tacoma, WA 98408

Tubercul	osis Treatment Agreement						
Name:	DOB:						
Address: Your doctor is requesting that you take tuberculosis medications. The Health Department will provide the tuberculosis medications Monday through Friday by "directly observed therapy" (DOT). This means you must swallow all of the pill while the outreach worker watches. The pills cannot be left with you, or anyone else, to take later in the day. There are no medications on weekends and holidays. Your doctor will decide how many doses of medication you need for treatment and only doses you take by DOT are counted.							
	et for you to take your medications. If you cannot meet us, please call If we are going to be late, or need to change the time of meeting, we edication doses in order to cure the TB.						
take with you, the Health Department requires one	r treatment course. If you must be out of town and need medicines to e week's notice. You will receive one-half credit for each dose that is at course to take longer. If you are gone longer than 2 weeks, the rds to your new residence.						
Your tuberculosis might be contagious, so the Hea school and recreational activities to decide who ne	lth Department will do TB skin testing. We will ask you about work, eds testing.						
	narge of your tuberculosis treatment, which includes prescribing your f you have any problems with your TB medicines, please call the doctor						
Mary M. " Peggy " Cooley, MSN, RN DOT Program Coordinator 253-798-2861	Sharon Reinsvold, BSN Nurse Epidemiologist 253-798-7689						
Patient or Representative	Date						
Health Department Representative	Date						

Date

Interpreter TBRXagreement

Tacoma- Pierce County Health Department 3629 South D Street Tacoma, WA 98418 253-798-6410

ACUERDO PARA EL TRATAMIENTO DE TUBERCULOSIS

Fecha de Cumpleanos:_____

Nombre:_____

Direccion:	
medicinas para la tuberculosis de lunes a viernes a traves usted debe de tomarse (tragarse) todas las pildoras que se asistencia publica lo observa. Las pildoras no pueden ser e sean tomadas mas tarde. No se entregan medicinas los fir	culosis. El Departamento de Salud le suministrara (le dara) las de "Terapia Directa Observada" (DOT). Esto significa que le den mientras un trabajador del servicio especial de dadas ese dia ni a usted ni a ninguna otra persona para que nes de semana, ni los dias feriados. Su doctor decidira cual es las dosis que usted tome con el DOT son las que son contadas.
asistir a su cita por favor llame al trabajador de servicios e nosotros vamos ha llegar tarde o necesitamos cambiar la la que tome todas las dosis de la medicina para poder curarso largas durante el curso de su tratamiento. Si usted tiene que para llevarsela con usted, el Departamento de Salud requi unicamente recibira medio credito por cada dosis que no si tratamiento tome mas tiempo. Si usted estuviera fuera por transferir su historia medica a su nuevo lugar de residenci Su tuberculosis puede ser contagiosa asi que el Departame preguntaremos acerca de su trabajo, escuela y actividades	nora de la cita nosotros lo llamaremos a usted. Es importante e de TB.Por favor no haga planes para salir de vacaciones ue salir de la ciudad por fuerza mayor y necesita la medicina iere que se le avise con una semana de anticipacion . Usted sea supervisada. Las vacaciones causaran que el curso del r mas de 2 semana el Departamento de Salud podria tener que a (lugar de vacaciones).
tuberculosis el cual incluye la prescripcion de la medicina	nfections Limited estan encargados de su tratamiento para la , ordenar sus examenes de laboratorio y las radiografias de su medicina para la TB por favor llame a Infections Limited al
Firma	Fecha
Departamento del Salud	Fecha
Translator	Fecha
TB Treatment Agreement-Spanish 7/00	

Case Management Treatment Plan for Active TB Disease

The purpose of this form is to provide a checklist to organize the gathering of information in a TB case to ensure the best medical and public health practices. Corresponding TB forms, both required and recommended, are listed with each component. (* denotes forms that are required by the state of Montana)

Patient Name	Date
Patient's contact information – 1. Confirmed/ 2. TB Case Mo	'Suspected Report of TB Disease* onthly Report*
3. TB Conta 4. DOT – T	d/Suspected Report of TB Disease* Monthly Report* act Investigation Report* reatment Record nostic Referral Form
Patient educator's name & dates of educati	on — 1. Monthly TB Patient Assessment 2. Treatment of Active TB Education Form
Method for prevention of transmission – 1.	Home Isolation Agreement
Planned course of antituberculosis drug the DOT plan	erapy – 1. Confirmed/Suspected Report of TB Disease* 2.TB Case Monthly Report* 3. DOT - Treatment Record 4. DOT Agreement
Estimated date of completion of treatment	 - 1. Confirmed/Suspected Report of TB Disease* 2. TB Case Monthly Report* 3. DOT - Treatment Record
Test results from initial medical evaluation	– 1. Confirmed/Suspected Report of TB Disease*
Medical history — 1. Confirmed/Suspected Rep 2. TB Case Monthly Report* 3. Monthly TB Patient Asse	

Diagnosis — 1. Confirmed/Suspected Repo 2. TB Diagnostic Referral For 3. Bacteriology Data Sheet	
Baseline tests, monitoring of activities, Drug therapy & side effects	, — 1. Confirmed/Suspected Report of TB Disease* 2. TB Case Monthly Report* 3. Monthly TB Patient Assessment 4. DOT - Treatment Record 5. DOT - Adverse Reactions & Side Effects 6. Bacteriology Data Sheet 7. Biochemistry Data Sheet
3. DOT - T	Monthly Report* TB Patient Assessment Treatment Record Adverse Reactions & Side Effects
Potential treatment adherence obstacle	es – 1. TB Case Monthly Report* 2. Monthly TB Patient Assessment 3. DOT – Treatment Record 4. TB Home Evaluation 5. Treatment Active TB Education Form
Personal service needs & social service	es referrals — 1. Monthly TB Patient <i>Assess</i> ment 2. TB Home Evaluation
Referrals for social services - 1. Monthly 2. TB Hom	TB Patient Assessment e Evaluation
3.	DOT - Agreement DOT - Treatment Record Monthly TB Patient Assessment Treatment of Active TB Education Form
-	. TB Case Monthly Report* . Monthly TB Patient Assessment 3. DOT Agreement

TB DISEASE MONTHLY PATIENT ASSESSMENT

Name: DO	B:	Date of Visit:	Interpreter:
Location of visit: Home Office Other _			
Case conference last done on:			
Type of TB: Pulm. TB Y/N			Date Of Last CXR:
Extra-pulm. TB Y/N Site:			Improved:
Currently infectious Y/N			Stable: Worse:
Other Medical Conditions	Medications / C	<u>hanges</u>	Education
None	Anti-coagulants		DX, Infection Vs. Disease
Asthma Cancer	Anti-hypertensiv	res	Transmission/Prevention
COPD Diabetes	Coumadin		Meds: Resistance/Side Effects
ESRD GI	HIV meds		General health care
Hep C / Hep B HTN	Immunosupressi	ves	HIV/AIDS information
Liver Pregnant	Insulin	:	Counseling & testing
Other:	Oral Hypo-glyce	emics	TB & HIV
Tobacco use Y/N	Othom		Diagnostic Procedures Community Resources
Cessation Counseling Y/N	Other:		
	Reactions to Me	A.	Other: Psychosocial
Assessment Weight:B/P:		EUS INH,RIF, EMB, PZA	<u>Psychosocial</u>
Pulse Oximetry :% LMP:	Jaundice	Y/N	Alcohol / Drug use
ruise Oximetry	Fever	Y/N	Behavioral / Mental Health
AFB:	Nausea	Y/N	
Sputum Urine Other	Light stools		Homeless Language barrier
Last date submitted:	Vomiting	Y/N	Cultural barrier
Due:	Dark urine	Y/N	Limited cognitive skills
Containers given for (date):	Abd.	Y/N	Transportation
Problems:		y INH,RIF, EMB, PZA	Long work hours
Troblems.	Rash	Y / N	No insurance
Lab work drawn:		Y/N	Inadequate food/income
HFP	Non specific INH		
CMP Y/N	Headache	Y / N	DOT
CBC Y/N	Malaise	Y / N	# Missed doses in past month
Other:	Fatigue	Y / N	Problems:
	Anorexia	Y / N	
Vision check:	Neurotoxicity II	NH, EMB	
Distance: Rt L	Paresthesia	Y/N	
Both: Glasses: Y/N	Dizziness	Y / N	
Color vision all plates seen: Y/N	Visual changes	Y/N	
Problems:	Distance	Y/N	Referrals:
	Hemolytic RIF		
Hearing screening: Y / N Results:	Bruising increa		
	Bleeding gums		
Balance: WNL ABN	Hematuria	Y / N	
	Hematochezia	Y / N	
Nurses' Comments:			·-
			
Re-interviewed for more contacts Y/N Con	nments:		
PHN Signature:			
			MT DPHHS 2/2007

MONTHLY TUBERCULOSIS CASE REPORT Submit 1st day of every month- <u>new information from last report only</u>

Department of Public Health & Human Services TB Program Cogswell Building, Room C-216 1400 Broadway, Helena, MT 59620 Phone: 406-444-0275; Fax: 406-444-0272 This Report is being submitted for: Patient Name: City: County:					Submitted By Agency: Phone:	: Year _		
Diagnostic l				20 u ny				
				nsecutive neg		sults	D.G.	
I CSL	late ollected	Resu	lt		Test		Date Collected	Result
AFB Smear					M.tube	erculosis Culture		
AFB Smear					M.tube	erculosis Culture		
AFB Smear					M.tube	erculosis Culture		
AFB Smear					M.tube	erculosis Culture		
AFB Smear					M.tube	erculosis Culture		
Other Tests: Most Recent Symptoms: Hospitalizat Medication DOT Plan (Self-Admini	() () ion: D - Treati describe stration erapy:	Cough Chest P Oate: ment ar e) i: (give sp	Date:_ : Date:_ : Date:_ : Adamad Adherence:_ :	oductive coughight Loss mitting Diagr ce:	h () I	esult:	() Nig	
Medication		Dose	Date Started	Projected I of Ther	_	Date Treatment Completed		re Meds Dc'd and reason side effects, resistance, moved
Isoniazid -INH					1 J		0	, , , , , , , , , , , , , , , , , , , ,
Rifampin - RIF	$\neg \uparrow$							
Pyrazinamide -	PZA							
Ethambutol - E	#							
Other:								
Therapy Co	mplete	d & Cas	se Closed: _			(This wi	ll be the fi	inal report)

MT DPHHS 2/2007

LTBI MONTHLY PATIENT ASSESSMENT

(LATENT TB INFECTION)

Name:		DOB: Date	of Visit:	Interpreter:	
Location of visit: Hom					
Case conference last do	one on:	_			
Other Medical Condition	ons	Medications / Char	iges	Education	
None			_ <u>-</u>		
Asthma	Cancer	Anti-coagulants		DX, Infection Vs. Disease_	
COPD	Diabetes	Anti-hypertensives		Meds: Resistance/Side Effective	
ESRD	GI	HIV meds		General health care	
Hep C / Hep B	HTN	Immunosupressives		HIV/AIDS information	
Liver	Pregnant	Insulin		Counseling & testing	
Other:		Oral Hypo-glycemic	c	TB & HIV	
other:		Orar Hypo-gryceniic	.3	Diagnostic Procedures	
T. 1	X7 / X7	Other:		Community Resources	
Tobacco use	Y/N	other.			
Cessation Counseling	Y / N			Other:	
		Reactions to Meds		Psychosocial	
<u>Assessment</u>		Hepatotoxicity INH,	RIF, EMB, PZA		
		Icterus	Y/N	Alcohol / Drug use	
Weight:	_ B/P:	Fever	Y/N	Behavioral / Mental Health	
		Nausea	Y/N	Homeless_	
Pulse Oximetry:	% LMP:	Light stools	Y/N	Language barrier	
ş 		Vomiting	Y / N	Cultural barrier	
Other:		Dark urine	Y/N	Limited cognitive skills	· · · · · · · · · · · · · · · · · · ·
<u> </u>		Abd.	Y/N		
Chest X-ray: date				Transportation	
chest A-ray. date		Rash	Y / N	Long work hours	
		Arthralgia	Y/N	No insurance	
				Inadequate food/income	
		Non specific INH, RI			
Lab work drawn:		Headache	Y/N	<u>DOT</u>	
*****		Malaise	Y/N	# Missed doses in past mon	<u></u>
HFP		Fatigue	Y/N	<u>Problems:</u>	
CMP Y/N		Anorexia	Y / N		
CBC Y/N		Neurotoxicity INH ,			
Other:		Paresthesia	Y / N		
		Dizziness	Y/N		
		Visual changes	Y / N		
		Distance	Y / N	Referrals:	
		Hemolytic RIF			
		Bruising increase	Y/N		
		Bleeding gums	Y/N		
		Hematuria	Y / N		
		Hematochezia	Y/N		
Nurses' Comments:					
				 	
PHN Signature:				Date:	
					MT DPHHS 2/2007
					2:11115 2:2001

Case name:			DOB		Rec	#		
LHD or PMD	Phone			Fax				
Diagnostic Evaluation:								
Cough, Sputum: thick/th		, H emopty	ysis, F ever, N i	ight S weats	s, M alaise	, Wt.Loss	s of1	bs
Diagnostic Microbiolog	•	AED	A ED14		C	411. 11141	TEGE	Г.
Date of spec 7			·			_	_	
1 2								te: MM
2								Not done
CXR ⁶ :							-	tot done
TREATMENT PLAN:	o 6 MONTI	H o OTHER	l:					
Pt. Wt. =			OTE: regimen &					
Start Month	1st <u>montn</u> 2	montn ³ 3 n	nonth 4 th month	5 month	6 month	/ montn	8 month	9 month
INHmg								
DIE ma								
RIFmg								
PZAmg								
EMBmg								
B6mg								
mg								
mg								
# DOT doses:								
(Initial phase Self Administered (Standard # doses injested/mo	of care is to be	on DOT: only ex		umstances w				
MONTHLY MONITOR:								
Side effects ¹								
Isolation ² Yes/ n/a								
Smear status ³ above								
Culture status ⁴ <u>above</u>								
Clinical Resp ⁵		·						
Chest X-ray ⁶		no prn			End of tx			
MD/clinical Evaluation								

TB Case Management Monitoring Record

(4/2003 sample)

Side effects: \emptyset = none noted, \mathbf{P} = problem: see progress notes (symptom review, labs as ordered, visual/color while on EMB)

² Sputum smear positive cases should be isolated until non-infectiousness is established by: demonstrate a good clinical response to treatment, AND have been on adequate TB treatment for 2 weeks, AND have 3 consecutively negative sputum smears for AFB.

³ Pulmonary cases: collect at least <u>one</u> monthly to document conversion to negative smear, then collect 2nd & 3rd to document non-infectiousness and release from isolation. Frequency of collection depends on severity of illness and diagnostic sputum smears.

⁴ Pulmonary cases: collect <u>one</u> monthly to document conversion to negative cultures

⁵ Clinical response: list letter code for persistent symptoms (eg/ C for cough), improved, or resolved. AFTER 2nd mo., eval the regimen. ⁶Initial: C=cavitary, Non-Cavitary; infiltrates, scaring, nodules, etc./prn=improved, stable, worse / End= improved, stable, worse

PAGE							
Client Name:DOB	Ado	dress:			Phone:	I.D	
Clinical Path - Dx.: Positive PPD			Physician:			KEY	,
OUTCOMES/GOALS: Client or caregiver will understand disease process and	screening proc	edures	_	DATE MET:	_	D = DemonstratesU = UnderstandsC = Complies	X = DoneI = Instruct/ReinstructVR = Variance
Client or caregiver will verbalize understanding of significare provider	cant occurrence	es and when to	call health			0 = None N/C=No Change	N/A = Not Applicable / = Did Not Assess
Client or caregiver will follow-up with recommended med	dical care within	() days of nu	ursing visit			Signature	Initials
Client or caregiver will verbalize understanding of possib	ole complication	s if follow-up no	t obtained				
Client or caregiver will leave with all questions relating to	condition ansv	vered					
Client or caregiver will verbalize understanding of impor-	ance of finishin	g treatment					
	1						
Date						Nurse's Evaluation and Pro	gress Notes
DIRECT CARE Initials							
Assess vital signs ☐ BP							
□ Pulse							
□ Respirations							
□ Temperature							
Allergies:							
Screening tests completed/Results:							
□PPD resultsmm Date:							
□Chest x-ray							
□Liver function							
□Visual Acuity							
□Sputum culture/gram stain/sensitivity							
Assess risk factors:							
□Medical conditions, including HIV							
□Living arrangements/Low income							
□Contact with people with active TB							
□Immigrants							
□Illicit drug use							
□Elderly or child < 4 years							
□Occupational exposure							
Assess relevant psych/social dimensions:							
☐ Insurance/income to cover screening & treatment							
□Able/willing to comply with treatment							
Assess for s/s of medication side effects:							
□Loss of appetite							

□ Dark colored urine

□Jaundice
□Rash/itching
□Blurred vision

Medication side effects (cont): Date			Nurses' Evaluation and Progress Notes
□Unusual pain in hands/feet/joints			
□Headache			
□ Dizziness/Drowsiness			
□Nausea/Vomiting			
□Convulsions			
□General tiredness			
Assess for s/s of active TB:			
□Cough			
□Hemoptysis			
□Chest pain			
□Fatigue/malaise			
□Weight loss			
□Fever/night sweats			
INSTRUCTION AND INFORMATION			
Prevention recommendations:			
□Finish medications			
□Testing contacts			
□Vitamin B6			
□Future PPD/x-rays			
Educational materials discussed and given:			
□S/s of active TB			
☐ Medication sheets			
□Signs and symptoms of complications			
□Active vs latent TB			
Referrals made to:			
□Physician			
□HIV testing			
Follow-up appointment kept with/date:			
Medications (list) and DOT (as applicable):			
Confidentiality of Records per protocol			
Informed Consent per protocol			
Next PHN visit or follow-up call			

Tuberculosis Treatment Record Directly Observed Therapy - DOT

Patient Name:	
Public Health Nurse:	
Agency:	
Physician:Pharmacy:	
Pharmacy:	
Prescription:	
•	

Date	Place of Visit	P	rescribed Oral me				*Adverse Reactions	Client Incentives	PHN Signature
Date	V 151t	INH	RIF	PZA	EMB		Reactions	Chefit Incentives	Bignature
		11/11	IXII.	IZA	LIVID				
1									
1									
1									
<u> </u>									
 									
 									
1									
-									
1									
1									
<u> </u>									
* 4 1			1 37	43.3. A		4 E	2 1/ 1/2	MDAGAD	

^{*} Adverse reactions = record on Monthly Assessment Form & consult with MD ASAP

Tuberculosis (TB) Directly Observed Therapy Agreement

To:	D.O.B.:
Patient name	
Because it is very important that you follow the doctor's you are being placed in a supervised treatment program Health Department.	
This program requires that you:	
Take your TB medicine while being observed by the Pubstaff as indicated below (days, time, and location):	lic Health Nurse or other designated
LOCATION:	
DAYS: Monday Tuesday Wednesday Thursday TIME:a.m. / p.m.	Friday (circle 2 days if bi-weekly)
We want to help you get better as quickly as possible and getting TB. If you do not follow these directions for treats and you could spread the disease to others. If you do not County may pursue legal action against you, which if condetainment for your treatment. PHN or Designee Signature	ment, your condition could worsen continue supervised treatment, the
I have read the above information, understand it, and ag	ree to the conditions.
Patient's Signature	Date
Interpreter Signature (if needed)	Date
Copy given to patient (PHN or Designee Ini	itials)

DIRECTLY OBSERVED THERAPY RECORD

lame of Patient:	Isolation Residence:	

Date	Time	Medicatio		Comments (List any other meds given, and/or if contact was attempted and patient wasn't home)	Staff Signature
		⊙ Isoniazid⊙ Pyrazinamide⊙ Pyrazinamide	Θ RifampinΘ Ethambutol		
		 ⊕ Pyrixodine (B₆) ⊕ Isoniazid ⊕ Pyrazinamide ⊕ Pyridoxine (B₆) 	⊙ Rifampin⊙ Ethambutol		
		 ⊙ Isoniazid ⊙ Pyrazinamide ⊙ Pyridoxine (B₆) 	Θ RifampinΘ Ethambutol		
		 ⊕ Isoniazid ⊕ Pyrazinamide ⊕ Pyridoxine (B₆) 	Θ RifampinΘ Ethambutol		
		⊕ Isoniazid⊕ Pyrazinamide⊕ Pyridoxine (B₆)	Θ RifampinΘ Ethambutol		
		⊕ Isoniazid⊕ Pyrazinamide⊕ Pyridoxine (B₆)	Θ RifampinΘ Ethambutol		
		⊕ Isoniazid⊕ Pyrazinamide⊕ Pyridoxine (B₆)	Θ RifampinΘ Ethambutol		
		⊕ Isoniazid⊕ Pyrazinamide⊕ Pyridoxine (B₆)	Θ RifampinΘ Ethambutol		
		⊕ Isoniazid⊕ Pyrazinamide⊕ Pyridoxine (B₆)	Θ RifampinΘ Ethambutol		
		⊙ Isoniazid⊙ Pyrazinamide⊙ Pyridoxine (B₆)	Θ RifampinΘ Ethambutol		
		⊕ Isoniazid⊕ Pyrazinamide⊕ Pyridoxine (B₆)	Θ RifampinΘ Ethambutol		
		⊕ Isoniazid⊕ Pyrazinamide⊕ Pyridoxine (B₆)	Θ RifampinΘ Ethambutol		

Idaho TB Contact Tracing Form—Return with CDC "Report of Verified Case of Tuberculosis Follow Up Report-2"

	e:tacts (use additional s				ear Rep	oorted: _	r	Number of Cor	ntacts Iden	tified:	
Name	Relationship to Case (family, co-worker, etc.)	Date First Evaluated	PPD Tested?	PPD Result	CXR?	CXR Result	Infection status (uninfected, infected, active TB, or unknown)	Started on PPx? (INH or other)	Date PPx Started	Date PPx Last Taken	PPX Completed? If PPx not Completed, Reason*:
Bob Contact	Brother of case	01/01/2000	Υ	10mm	Y	Negative	Infected	Y – INH	01/06/2000	05/06/2000	No. 2

^{*}Reasons for not finishing PPx (pick the best option): 1. Death; 2. Moved AND unable to locate for follow-up; 3. Adverse effect of medication; 4. Contact chose to stop despite indication for continuation of PPx; 5. Contact lost to follow-up; 6. Provider decision

TB CONTACT INVESTIGATION REPORT

ŀ	of _	

Today's Date:	Submitted by:	Agency:
	; 2. Less than 5 yo; 3. Contact has med risk factor (HIV); 4. Exposed (XR consistent with previous TB; 8. 5-15yo of age	during medical procedure; 5. Exposed congregate setting;

Case Name:	County/Tribal/ IHS:

	-	1							T		
List of Contacts:		Contact Risk Factors	Initia	al TST		TST weeks	If patient old, mus	C-Ray t less than 5 years at have both r & lateral x-rays	Treatme	nt of LTBI	If Treatment is not
1. Name2. Relationship to TB case3. Address	DOB	And Dates (see above)	Date	Result mm	Date	Result mm	Date	Result	Med & Start Date	Completion Date	completed give reason
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address
1											Death Adverse Reaction Patient Decision Active TB developed Lost to follow-up Moved - provide address



Tuberculosis Contact Investigation Form

ubmitted By:	
Oate:	_

	Case													Contact			
Name: (last) (first)	(MI)	(also kn	own a	s)					Pri	ority	of exposed c	ontact	Conta	act Investigation		Contact Risk Fac	
							(1		c .	OI I		1 (" ','				rk Y =Yes or N = No in	chart below)
DOD 1							(ple	ase re	ter to	CI In	structions for	definitions)	Date		1. Housel		
DOB:	Age:	RVC	1:				$ \Box $	Cater	orv 1	· Sm	ıear nositive	or cavitary ches				nan 5 years of age	
Morbidity Date:		_1					┤╚	x-ra		. 511	icai positive	or cavitary the	identified			t has medical risk fac	
Moroidity Date.								••,	J				Date			ed during medical pro	
County:	Comi	ments:						Categ	ory 2	: Sn	near negative	•	Interviewed:			ed congregate Setting	
							J									ds duration environme	ent limits
Туре:			_		Cavita	ry		Categ	ory 3	: Su	spect case		Date of		/. 5 - 15 y	years of age	
Pulmonary Non Pu	ilmonary C	XR Resu			.	٠,							Evaluation:_		—		
T. 11 M	T D .		1 .		lonca	vıtary		1	1	1	more v	11 / 055	G.D. II			4 AT EDI	****
Full Name	Date	_				4.					TST B	Results/ QFT-	G Results	Current	Treatme	ent of LTBI	
of Contact	of	013				ıre		7.0		8				Chest			Completion
	Birth	ıgə	p	s	ų.	SC	ب	iits	LS	TB				X-Ray			Date or
		ät	hol	years	risk	ğ	Se	lim	ea_	prev							Discontinued
		*Exposure category	Household		d r	Medical exposure	Cong Set	Enviro limits	15 years								Due to:
		m	no	5	Med	E	5	vir	-1	CXR-		•					
		S00	H	V	_	Ä		$\mathbf{E}\mathbf{n}$	Ń	X	**Prior Positive	Initial TST or QFT-G	8 – 10 week retest				
		lx;				Ĭ				C	Pr Sit	nitia ST c FT-(et e				
		*									* A	1 H O	∞ × ï				
1.												Date:	Date:	Date:	Yes Date:_		
1.												TST mm:	TST mm:	☐ Normal	Drug (s)		
												QFT-G:	QFT-G:	Abnormal	☐ No Reaso	on:	
2.												Date:	Date:	Date:			
2.												TST mm:	TST mm:	☐ Normal	<u>Drug</u> (s)		
												QFT-G:	QFT-G:	Abnormal	No Reaso		
3.												Date:	Date:	Date:	Yes Date:_		
												TST mm: QFT-G:	TST mm: QFT-G:	☐ Normal ☐ Abnormal	Drug (s) No Reaso		
1												Date:	Date:	Date:	Yes Date:		
4.												TST mm:	TST mm:	□ Normal	Drug (s)		
												QFT-G:	QFT-G:	Abnormal	□ No Reaso	on:	
5.												Date:	Date:	Date:	Yes Date:_		
<i>J</i> .												TST mm:	TST mm:	Normal	Drug (s)		
												QFT-G:	QFT-G:	☐ Abnormal	☐ No Reaso	on:	
*Exposure Category	**Prior P									n-GC	OLD Results			te or discontinued	due to:		
H= High	(1) = Follows							= Posi					C) = Completed tre				Discontinued Meds
M= Medium	(2) = Followskip	ow-up no	ot need	led				= Neg					D) = Died during tr	reatment		(R) = Refused	
L= Low							(3):	= Inde	termi	nate		,	L) = Lost	1.00		(T) = TB Disea	se Diagnosed
												(N	M) = Moved & Red	cords Referred			

TB Contact Investigation Summary Due at the completion of each contact investigation - After all contacts on treatment for LTBI have completed therapy or have discontinued drug therapy Montana Department of Public Health & Human Services Today's Date _____ TB Program, Cogswell Building, Room C-216 Submitted by _____ Date Case Reported _____ 1400 Broadway, Helena, MT 59620 Phone: 406-444-0275; Fax: 406-444-0272 County _____ Case Name ____ ___ pulmonary TB with AFB sputum smear positive 1. The case had: ___ pulmonary TB with AFB sputum smear negative (check one) ___ non-pulmonary TB other 2. Number of contacts identified _____ 3. Number of contacts evaluated (initial TST placed & read, follow-up TST placed & read if indicated, and chest x-ray) 4. Number of contacts that were diagnosed with active TB disease as a result of this contact investigation _____ (This will trigger a separate contact investigation.) 5. Number of contacts that were diagnosed with latent TB infection (LTBI) as a result of this contact investigation _ a. Number that started treatment for LTBI ____ b. Number of contacts that completed recommended treatment _____ 6. For contacts not completing treatment for LTBI: a. Number who died before completing therapy __ b. Number who moved before completing therapy with no follow-up information _____ c. Number who developed active TB disease during the course of therapy d. Number who stopped treatment due to side effects/adverse reactions _____ e. Number who chose to stop treatment without any contraindications _____ f. Number who stopped treatment on provider's advice _____ g. Number lost to follow-up _____ Evaluation Indices for Contact Investigation: 1. Percentage of contacts evaluated _____ (MT goal: 95% of contacts to AFB-positive smear cases are evaluated) 2. Percentage of contacts who were diagnosed with LTBI _____ 3. Percentage of contacts with LTBI who completed treatment _____ (MT goal: 80% of contacts with LTBI will complete treatment)

HOME ISOLATION AGREEMENT DOB: _____ Patient Name: _____ Street Address: Phone: City/State _____ ZIP: The above named patient has a communicable disease in a communicable stage and has been placed in isolation by their physician and/or the County Health Officer. Therefore, the following conditions must be followed: The Patient agrees to: 1. Remain isolated to his/her private residence (or the address above) until determined to be non-infectious. 2. Not have contact with persons who do not reside at the above residence; therefore, visitors will be not be allowed in the residence until the isolation has been rescinded. 3. Allow TB Control Staff to monitor compliance with home isolation including unscheduled visits and phone calls. 4. Go to medically necessary medical appointments AND agrees to wear a mask when going to medical appointments until isolation has been rescinded Non-infectious status will be determined by subsequent sputum smears, compliance with TB treatment, and clinical response to treatment. Isolation will be rescinded by the County Health Department as soon as the patient is determined to be non-infectious and on adequate Directly Observed Therapy for tuberculosis. I understand that if I fail to comply with these conditions, further legal action may be taken, possibly resulting in court ordered detainment. I have read the above information and understand it. Patient's Signature Date Interpreter's Signature (if needed) Date PHN or Designee Signature Date Copy given to patient _____ (PHN or designee initials)

MT DPHHS 2/2007

SAMPLE: to use with all infectious TB patients Print on letterhead

HOME ISOLATION AGREEMENT

Date:	
Patient Name:	DOB:
eet Address:	Phone:
City:	ZIP:
communicable stage and has been placed in isolation by hereafth Administrator or Health Officer for the Court 433.010 Spreading disease prohibited states, "No person so from any communicable disease within this state." Therefore the followed: 1. The patient agrees to remain isolated to his/her private above) until determined to be non-infectious. 2. The patient agrees to not have contact with persons where residence; therefore, visitors will be not be allowed in has been rescinded. 3. The patient agrees to allow TB Control Staff to monitorisolation including, unscheduled visits and phone calls the patient may go to medically necessary medical apwear a mask when going to medical appointments until	is/her physician and/or the nty. Oregon Revised Statute hall willfully cause the spread the following conditions must residence (or the address no do not reside at the above the residence until the isolation or compliance with home the compliance with home the compliance with home the pointments AND agrees to
TB treatment, and clinical response to treatment. Isolation	n will be rescinded by the to be non-infectious and on one, further legal action may
Tuberculosis Control Staff Person Signature	Date

Instructions for Patients with Infectious Tuberculosis (TB)

Prepared by the Communicable Disease Control Program (208) 327-8625

People with infectious TB can spread the infection to others until medications have made the person noncontagious (not able to spread TB germs). This usually takes between 2 weeks and 2 months. It is very important to prevent others from getting infected. Until a public health worker from Central District Health Department tells you that you are no longer contagious, please follow these instructions carefully.

• Stay isolated at your residence.

- You should stay at your residence except for doctor's appointments. If you have a
 necessary doctor's appointment with a doctor who does not know you have TB,
 you should inform the office staff ahead of time.
- You should not be inside your residence or a car or a building with anyone who is not a member of your immediate household.
- o If you have to go to a doctor's appointment, you must wear a mask outside your home, when you're in a car with others and when you are inside the medical clinic.

Visitors should not come inside your home.

- o In an emergency if a visitor must come inside your home, wear a mask when you answer the door. Warn the visitor that without wearing a mask, he or she is in danger of accidentally becoming infected with TB. Immediately give the visitor a mask when they enter your home. Both you and your visitors must wear masks the entire time they are there. Make the visit as brief as possible. Only in extreme emergencies should children under 5 years visit your home.
- You may visit with people outdoors without wearing a mask. Stay at least one arm length away from others.
- Do not go to work, religious services, school or other places.
- Cover your nose and mouth with disposable tissues when coughing.

Patient	Date	Central District Health Dept. Rep.
Your signature below indicates	3	3 0
sure that people who are contact	gious with TB stay isola	ated until they are no longer contagious.
3 ·		ill pursue legal action to attempt to make



ISOLATION INSTRUCTIONS

)				
EALTH	Name:	DOB:	Date:	
are able to spread to same air in a room	etermined that you may be/are the disease through coughing, or house with a contagious pe ensils or bathroom facilities.	sneezing, singing or shoutir	ng. TB is spread when peop	ole share the
different for each p	at home until the doctor notion berson. Do not go into building not prohibit you from obtaining	gs where there are people, i	ncluding stores, church, sch	
mask you wore at that you have contact 253 798-6410, the	er alternative, you may go insiderations Ltd. for your appoin agious tuberculosis. If there are press "0". Wearing a mask a you were diagnosed has already	the timent is sufficient. When your questions, call the Tacom at home is not necessary, be	ou enter a facility, you mus aa-Pierce County Health De	t notify them partment at
•	on period, no one should enter the air and can infect person			lence. The
curtains, shades or	lled by sunlight and is diluted blinds open to let sunlight in. er your mouth and nose when o	During warm months, plea		
	s isolation may be difficult for bility of the Health Departmen n be cured.			
If you have any qu	estions, call Dr. Lawrence Sch	wartz, Dr. Marina Arbuck	or the Health Department.	
	derstand the above instructions I am no longer contagious.	s and information. I agree t	o follow these instructions	until notified
Patient or Represen	ntative Signature	Date		
Health Department	t Representative	Date	_	
Translator			_	

Tacoma-Pierce County Health Department 3629 South D Street Tacoma, WA 98418 253-798-6410

INSTRUCCIONES PARA UN AISLAMIENTO (INCOMUNICACION – CUARENTENA)

FECHA DE CUMPLEANOS:_____FECHA:____

Su Doctor ha determinado que usted (ustedes) puede (puede significa que usted (ustedes) tienen la posibilidad de propag cantando o gritando. TB se puede propagar cuando la gente alguien que este contaguiado (o sea que tenga tuberculosis). besos, ropa, utensilios para comer (cucharas, tenedores, cuclavatories).	ar esta enfermedad a traves de un catarro, un estornudo, e comparte el mismo aire en un cuarto o de una casa con TB no se propaga compartiendo comida, abrazos o
Usted necesita quedarse en su casa hasta que el doctor le no propagador de esta enfermedad). El periodo de tiempo para en donde hay gente, esto incluye tiendas, iglesias, escuelas o tiempo de asilamiento) no le prohibe a usted obtener servici	a la cur es different con cada persona. No vaya a edificios o lugares de trabajo. El estar aislado (o sea durante el
Si usted no tiene otra alternativa, usted puede entrar a un ed ajustada. La mascara que usted usa para sus citas en Infecci facilidad (edificio) les debe de notificar de que usted tiene u Departamento de Salud del Condado de Tacoma-Pierce al te "0". No es necesario que use la mascara en su casa porque diagnosticado, ya estuvo expuesta al contagio.	iones Ltd. es suficiente. Cuando usted entre en una una tuberculosis contagiosa. Si tiene preguntas, llame al elefono 253 – 798 6410, despues marque el
Durante este periodo de aislamiento, nadie debe de visitar o residencia. La bacteria permanece en el aire y puede contamen la casa.	
El germen de TB se puede matar con la luz del sol y es dilui cuarto. Por favor trate de mantener las cortinas o persianas meses calientes, por favor abra las ventanas para que permit cubrise la boca y nariz cuando tosa o estornude.	abiertas para dejar entrar la luz del sol. Durante los
Nosotros nos damos cuenta de que este aislamiento es difici publica y esta es la responsabilidad del Departamento de Sa prevenir si se toman precausiones y se puede curar.	
Si usted tiene alguna pregunta, llame al doctor de Infeccione	es LTD (428-8700, o al Departamento de Salud.
He leido y entiendo las instrucciones e informacion arriba n Instrucciones hasta que el medico me notifique de que ya no contagie a nadie).	
Firma	Fecha
Departamento Del Salud	Fecha
Translator	Fecha

Isolation Instructions-Spanish 7/00

NOMBRE:__

VOLUNTARY ISOLATION/QUARANTINE AGREEMENT

I,, date of birth	, gender
(full name - please print legibly)	
M F, have agreed to be [] isolated [] quarantined	
at:	
(premises subject to isolation and quarantine)	
pursuant to WAC 246-100-040 et seq. I understand that my isolation or quarantine	
commences on (moment of signing) and	,
(date) (time)	
and will remain in effect for days, unless rescinded by the health officer.	
Suspected Communicable Disease or Infectious Agent if Known: Tuberculosis Madical Basis on Which Designer to Isolate on Operanting Is Instifical.	
Medical Basis on Which Decision to Isolate or Quarantine Is Justified:	
[] You are suspected of having been exposed toare potentially currently infectious to others.	and
[] You have been diagnosed with an active case ofyou are in all likelihood currently infectious to others.	and
[] Other:	
Special Instructions:	

abide by this Voluntary Isolation	ection of your own health and that of othen/Quarantine Agreement. If you have any sistance in complying, please call:	·
quarantine, or may petition the S	ur voluntary compliance, may mandate is Superior Court for an order authorizing i n or quarantine for a period up to 30 days	solation or
	Local Health Officer or His Des Tacoma-Pierce County Health	_
	IMPORTANT NOTICE	
accordance with WAC 246-100-05 to afford legal counsel, then couns you should request the appointmer counsel, then you have an opportutional translator, one will be provided for	Superior Court for release from isolation or of 55. You have the right to legal counsel. If you el will be appointed for you at government on the of counsel at this time. If you currently have nity to contact that counsel for assistance. If you, and a copy of all relevant documents of plete copy of your rights shall be attached to	ou are unable expense and ave legal you require a will be sent to
I,		that I have
received a copy of the Voluntary or had read to me said Order an	Isolation/Quarantine Agreement, and the d that I understand and agree to the termily entering isolation or quarantine.	at I have read
Signed, 20	Dated this	day of
Internal use only:		
Dated thisday of Date copies of Written Order wa Met	_, 20 as delivered to person or group of persons thod of delivery: personal service	: ; registered
mail If the or	rder relates to a group and the order is po	osted, date
1,	-	

Aislamiento Voluntario/ Acuerdo sobre Cuarentena

I,	, fecha d	le nacimiento		
(Nombre completo, le	egible)			
Genero M FYo esto	y de acuerdo en	[] aislamiento	[] cuarenter	na
en:	al lugam quieta e e	islamianta é ayanan	tono	
(6	n rugar sujeto a ar	islamiento ó cuaren	lena)	
conforme con la ley WA cuarentena comienza en	(el momento en que f	firme).	que mi aislamiento	ó
(fecha)	(h	ora)		
y se mantendrá en efecto Departamento de Salud.	por days	, recindible solamer	nte por el Oficial de	el
Mis derechos han sidos ser aislado ó puesto en o			es por las que teng	go que
Agente Infeccioso ó Enfe	ermedad Comunic	cable: Tuberculosi	<u>s</u>	
Decisión médica por la cuarentena:	que se ha decidio	do aislar ó poner a	este paciente en	
[] Se sospecha que Ud infectar a otros.	ha sido expuesto	a	у р	uede
[] Ud ha sido diagnostic la posibilidad que infecte		activo de		_ y existe
[] Otro:				_
Intrucciones Especiales:				

Es importante para la protección de su salud y la de otros que Ud cumpla con el acuerdo de aislamiento ó cuarentena. Si Ud tiene alguna pregunta sobre este acuerdo ó necesita ayuda llame a:					
El oficial del Departamento de Salud puede pedir su acuerdo voluntario, demandar su aislamiento ó pedir una orden de aislamiento ó cuarentena por un periodo de 30 days a la Corte Superior.					
Oficial de Salud Local ó person Departamento de Salud del Co					
	Noticia Importante				
a la ley WAC 246-100-055. Ud to por un consejero legal, un consejedirlo en este momento. Si Ud to contactarlo ahora y pedir asistente.	liberado de su cuarentena a la Corte Superior de acuerdo ciene derecho a consejeria legal. Si Ud no puede pagar jero sera designado a Ud a costo del gobierno y Ud debe tiene un consejero, entonces Ud tiene una oportunidad de cia. Si Ud require un traductor, dejenos saber. Copias de oveidos en su idioma. Un acta completa de sus derechos				
copia del acuerdo de mi cuarer	, admito que he recibido una ntena ó aislamiento voluntario y entiendo los terminos de acuerdo en comenzar mi aislamiento ó cuarentena				
Firma					
Para uso oficial:					
M	nviadas a la persona ó grupo de personas: letodo de envio:; servicio				
un grupo v la orden esta al tan	gistrado Si la orden se relaciona a to, fecha y lugar:				

ORDERS TO VOLUNTARILY COMPLY WITH TUBERCUORSIS CONTROL MEASURES (sample2004)

HEREBY REQUESTS THE	R or HEALTH OFFICER OF _ FOLLOWING:	(COUNTY
		DATE:	
Signature:	Title:	of	County
Orders Shall Remain In Effec	et Until Rescinded By		·
ORDERS ISSUED TO:			
Address:			
Date of Birth:	, OR		
ENERAL CONTROL MEASURE	apeareraa		
plation to place of residence or other	SPECIFICS You are hereby ordered isolated at the second control of the second control o	he following location	on on the following
cation RS 433.006 and ORS 433.010	You are hereby ordered isolated at the terms and conditions:	he following location	on on the following
cation RS 433.006 and ORS 433.010	You are hereby ordered isolated at the terms and conditions: LOCATION: Address		on on the followin
cation RS 433.006 and ORS 433.010 AR 333-019-0000	You are hereby ordered isolated at the terms and conditions: LOCATION: Address	regon	_
cation RS 433.006 and ORS 433.010 AR 333-019-0000	You are hereby ordered isolated at the terms and conditions: LOCATION: Address	regon ne above location u County Healert for TB and are cay only leave your	ntil you are deem alth Department. Cleared byOplace of isolation
eation RS 433.006 and ORS 433.010 AR 333-019-0000	You are hereby ordered isolated at the terms and conditions: LOCATION: Address	regon ne above location u County Hea ent for TB and are cay only leave your p the hospital, with a nust return directly om the medical app	ntil you are deem alth Department. cleared by(place of isolation the condition that to your place of pointment or hosp
olation to place of residence or other ocation RS 433.006 and ORS 433.010 AR 333-019-0000 ate Rescinded://	You are hereby ordered isolated at the terms and conditions: LOCATION: Address	regon The above location use above location use above location use at the location are considered as a constant of the hospital, with a construction on the medical apportant point of isolation and incomplete in the location of isolation in the location and incomplete in the location is above.	ntil you are deem alth Department. cleared by Oplace of isolation the condition that to your place of pointment or hospidents, will be all on.

 $\overline{\mathbf{V}}$

Ø	Required medication and Directly Observed Therapy ORS 433.006 and ORS 433.010 OAR 333-019-0000	You are hereby ordered to complete the following appropriate prescribed course of medication: 1. TB medications must be taken once daily. 2. All the TB drugs will be dispensed and observed once daily as follows for the Initial Phase of treatment: [Interiorial (INII)]
	Date Rescinded://	Isoniazid (INH)mg Rifampin (RIF)mg Pyrazinamide (PZA)mg Ethambutol (EMB)mg 3. The Continuation Phase: The physician will adjust the medication regimen when culture and susceptibility results are known and after all the doses from the initial phase have been taken.
		LOCATION:
		DAYS: Monday-Tuesday-Wednesday-Thursday-Friday (on Friday, a package of TB medicine for Saturday and a package for Sunday will be left for you to take on the appropriate day)
		TIME: atam / pm
		CONDITIONS:
		County Public Health Staff will dispense your medication and observe you ingesting your medication at the above location, on the days specified above, at the time specified. This schedule may be changed upon mutual agreement of you and
		County Public Health Staff: a. b. c.
		Phone number: () 3. This schedule may also change to ingesting medication two times a week, upon recommendation of the physician, and when you can tolerate the increased doses.
	Exclusion from workplace or other place.	You are hereby ordered excluded from the following locations on the following terms and conditions:
	ORS 433.006 and ORS 433.010 OAR 333-019-0000	Work: School:
	Date Rescinded://	Other: Any public building or place (except for medical appointments as discussed in the isolation section).
		Once you are on adequate treatment and are not infectious, the County Health Department will rescind this order.
V	Additional orders	
	ORS 433.006 and ORS 433.010	1. Follow all TB control measures.
	OAR 333-019-0000	Appear at all appointments given you by your treating physician and byCounty Health Department.
	Date Rescinded://	Comply with your treating physician's requests for testing necessary to monitor your response to treatment and to monitor for side effects.

INDIVIDUALIZED ASSESSMENT OF YOUR CIRCUMSTANCES

The individualized assessment of your circumstances or behavior constituting the basis for the Administrator/Health Officer to issue this order is as follows:

List ALL details of your reasons for issuing orders: e.g./

- 1. You were prescribed TB medications that you did not take (dates of missed doses)
- 2. You currently are refusing to take your TB medication.
- 3. You are currently refusing: (medical exams (sputums, blood lab work, etc)
- 4. You were diagnosed with active TB in _____ and eloped from care before completing treatment.
- 5. Per your physician's report you have been non-compliant with other medical treatment recommendations:

a.)

b.)

c.) *etc.*

6. Unstable lifestyle: no permanent housing (living with friends, family, or at a shelter), unemployed, psychiatric diagnosis not well controlled, etc.

1. The following less restrictive treatment alternatives were attempted in your and were unsuccessful:

(Samples: if none, state so & give reasons for giving orders initially - e.g./ past history of non-compliances) (if past TB treatment history, list:)

- a. Voluntary self-ingestion of TB medications (dates) with documented non-compliance (e.g./pill counts off, pharmacy check = patient did not refill TB meds, etc.)
 - b. Voluntary attendance at medical appointments (PMD reported patient missed the following appointments:)

2. The reasons less restrictive treatment alternatives were considered and rejected in your are as follows:

- A. Attempt at self-administration again. Rejected because:
 - 1) TB is treatable and curable IF medications are taken as directed. If untreated, 25% of cases die within 2 years, 50% die within 5 years, 25% remain alive infecting others in the community.
 - 2) Drug resistance can develop quickly if patients do not take their medication correctly.
 - 3) If drug resistance develops, the chance for a successful cure decreases and could result in your death
 - 4) Cases with a history of non-compliance with treatment usually continue with non-compliant behavior if treatment is not directly observed. (add to statement, if appropriate: You have demonstrated non-compliant behavior in the past as discussed above.)
- B. Isolation at home without TB treatment. Rejected because: (*list reasons- see samples below*)
 - 1) The patient does not live alone, and with untreated TB, could infect other residents of the household.
 - 2) There are young children in the home. Young children infected with TB can rapidly develop fatal forms of TB.
 - 3) The patient is currently medically fragile as evidenced by ______ and needs assistance with daily living so cannot live alone.

You are also	ordered to	submit to	a photograph	for purposes	of identification.	(optional -
if photos are	possible)					

Failure to comply with this order may subject you to further legal action, including jail.

Signature of person	
serving notice:	Date:
Signature of	
patient:	Date:
(if case refuses, the person serving the no	otice should write that in on the patient signature
line)	
Signature of	
interpreter:	Date:
(if needed)	

Interjurisdictional Tuberculosis Notification

Jurisdiction city		county		ate	Date sent	
Contact person		Phone	()		FAX ()
	State where reported:		RVCT#	□Convertor		_
☐ Suspect case		tRea	ictor LTBI	Convertor		ce case investigation
Patient name	Last	First	M	iddle	Sex	□Male □Female
Date of birth	///	Interpr	eter needed?	No □Yes, specif	y language	
New address	Number/Street/Apt. City/State/ZipCode					White □Black □Asian m.Indian/Nat.Alaskan.
New telephone (New health provide)	Known (name.	address, phone)	_		ther://
Insurance source:		Medicaid	Private	Medicare Phone	·	
Laboratory info	rmation for	this referred ca	se/suspect	index case for	this contact	not applicable
Date	Specimen type	Smear	Culture	Susceptibility		
Site(s) of disease: Date 1 st negative TB skin test #1:D	smear//	Not yet Result	Dat) specify all e 1 st negative cultu skin test #2: Date		/ Not yet / Resultmn
Contact/LTBI In TST #1 Date CXR Not Done Last known expos	/		_mm T rmal Otl			Resultmn
Medications	☐ this referred case/s	suspect	s referred contac	t/LTBI _{Planne}	l completion dat	te/
Drug	Dose	Start date	Stop da	4	_	t date/
						2x W 3x W
				Last DO	OT Date	/
				Adhere	nce problems/si	gnificant drug side effects
Comments						
Case Follow-Up	In 30 days repor	t to referring juris	diction if located	or not located and	report final out	come.

No follow-up requeste

Other Follow-Up

Follow-up requested (form attached)

Interjurisdictional Follow-up Form

3	30 day status:		not located		
Return to:					
Name		Fax	number		
Jurisdiction		Pho	ne number		
D. (*)			D	C1 : 41	/ /
Patient name	First	Middle	Dai	te of birth _	//
New address					
Number	Street/Apt.	City	St	ate	Zip Code
New telephone ()			Sex:	Male	Female
Case: (Send RVCT F/U2 to	o reporting jurisdict	ion)			
Completed:/	/ Moved t				
□Died	□Lost (afi	city ter initially located)	county Never	located	state
☐Uncooperative or refus					
Suspect:					
□Verified by lab	□Verifie	□Verified by clinical If verified, and original			
□Verified by provider	□Not vei	rified	submits RVCT, complete case outcome above.		te case
□Other:					
Contact:					
□No follow-up perform	ed Never 1	located			
□Evaluated: □ Class II	□ Class III □Class	IV □No infect	ion		
☐Started treatment	□Continu	uing treatment	□Other:		
LTBI/Convertor:					
□No follow-up performe	d □Never l	located	□Started	☐Started treatment	
□Continuing treatment	□Other:				